Reported 2 months ago
Moderna has reduced its 2024 sales forecast for COVID-19 and RSV vaccines by up to $1 billion, anticipating minimal sales in the EU market. The company now projects annual revenues between $3 billion and $3.5 billion, a stark decrease from previous estimates of $4 billion. This shift comes after struggles to secure agreements with the EU, alongside competitive pressures from rival vaccines and potential delays in international sales. Amid a reported net loss of $1.3 billion for the second quarter, Moderna aims for growth in 2025, banking on newer mRNA products.
Source: YAHOO